Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Merck & Co Inc (NYSE:MRK)

56.24
Delayed Data
As of Dec 15
 0.00 / 0.00%
Today’s Change
53.63
Today|||52-Week Range
66.80
-4.47%
Year-to-Date
MRK Regular Dividend: MRK began trading ex-dividend on 12/14/17. A $0.48 dividend will be paid to shareholders of record as of 12/15/17.
Merck's Keytruda Misses Primary End Point for Gastric Cancer
Dec 15 / Zacks.com - Paid Partner Content
Novice Trade: Pfizer
Dec 13 / TheStreet.com - Paid Partner Content
Bristol-Myers' Opdivo/Yervoy sBLA for RCC Accepted by FDA
Dec 15 / Zacks.com - Paid Partner Content
Merck's Keytruda Gets FDA Priority Review for Rare Lymphoma
Dec 12 / Zacks.com - Paid Partner Content
US Market Indexes Lower on Thursday
Dec 15 / GuruFocus News - Paid Partner Content
US Market Indexes Higher on Monday
Dec 12 / GuruFocus News - Paid Partner Content
Pharma Stock Roundup: Teva Announces Major Job Cuts, Lilly Provides 2018 Outlook
Dec 15 / Zacks.com - Paid Partner Content
4 Drug/Biotech Stocks That Could Be Buyout Targets in 2018
Dec 11 / Zacks.com - Paid Partner Content
Teva Options Jump to Record Amid New CEO's Latest Bid for Turnaround
Dec 14 / TheStreet.com - Paid Partner Content
Novo Nordisk's Semaglutide Gets FDA Approval for Diabetes
Dec 06 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close56.24
Today’s open56.23
Day’s range55.75 - 56.37
Volume22,580,659
Average volume (3 months)10,310,545
Market cap$153.4B
Data as of 4:00pm ET, 12/15/2017

Growth & Valuation

Earnings growth (last year)-9.62%
Earnings growth (this year)+4.29%
Earnings growth (next 5 years)+4.30%
Revenue growth (last year)+1.86%
P/E ratio54.1
Price/Sales4.15
Price/Book3.86

Competitors

 Today’s
change
Today’s
% change
NVSNovartis0.000.00%
PFEPfizer0.000.00%
SNYSanofi0.000.00%
ABBVAbbVie0.000.00%
Data as of 4:02pm ET, 12/15/2017

Financials

Next reporting dateFebruary 2, 2018
EPS forecast (this quarter)$0.94
Annual revenue (last year)$39.5B
Annual profit (last year)$3.9B
Net profit margin9.93%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chairman, President &
Chief Executive Officer
Kenneth C. Frazier
CFO &
Executive Vice President-Global Services
Robert M. Davis
Corporate headquarters
Kenilworth, New Jersey

Forecasts